This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Ferrous asparto glycinate
- DrugBank Accession Number
- DB11169
- Background
Ferrous asparto glycinate is an iron-amino acid chelate. It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Iron unknown E1UOL152H7 7439-89-6 XEEYBQQBJWHFJM-UHFFFAOYSA-N Ferrous cation ionic GW89581OWR 15438-31-0 CWYNVVGOOAEACU-UHFFFAOYSA-N - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Cavan One Ferrous asparto glycinate (7 mg/1) + Calcium (150 mg/1) + Calcium ascorbate dihydrate (25 mg/1) + Cholecalciferol (170 [iU]/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Doconexent (260 mg/1) + Folic acid (1 mg/1) + Icosapent (40 mg/1) + Iron (20 mg/1) + Linoleic acid (30 mg/1) + Pyridoxine hydrochloride (25 mg/1) + alpha-Linolenic acid (30 mg/1) Capsule, gelatin coated Oral Seton Pharmaceuticals 2009-10-30 2011-11-27 US 
Chromagen Ferrous asparto glycinate (25 mg/1) + Ascorbic acid (60 mg/1) + Cyanocobalamin (10 ug/1) + Ferrous fumarate (50 mg/1) + Folic acid (250 ug/1) + Gastric intrinsic factor (100 mg/1) + Levomefolic acid (750 ug/1) + Zinc (12 mg/1) Capsule Oral Avion Pharmaceuticals, Llc 2017-01-10 Not applicable US FeRiva FA Ferrous asparto glycinate (36.7 mg/1) + Ascorbic acid (175 mg/1) + Biotin (300 ug/1) + Cupric oxide (1.5 mg/1) + Cyanocobalamin (12 ug/1) + Docusate sodium (50 mg/1) + Ferrous bisglycinate (36.7 mg/1) + Ferrous fumarate (36.7 mg/1) + Folic acid (1 mg/1) Capsule, gelatin coated Oral Avion Pharmaceuticals, Llc 2015-01-01 Not applicable US Folcaps Omega-3 Ferrous asparto glycinate (7 mg/1) + Calcium (150 mg/1) + Calcium ascorbate dihydrate (24 mg/1) + Calcium threonate (1 mg/1) + Cholecalciferol (170 [iU]/1) + Doconexent (260 mg/1) + Folic acid (1 mg/1) + Icosapent (40 mg/1) + Iron (20 mg/1) + Pyridoxine hydrochloride (25 mg/1) + alpha-Linolenic acid (30 mg/1) + alpha-Tocopherol acetate (30 [iU]/1) Capsule, gelatin coated Oral Mayne Pharma 2011-01-03 2016-12-31 US Integra F Ferrous asparto glycinate (62.5 mg/1) + Ascorbic acid (40 mg/1) + Ferrous fumarate (62.5 mg/1) + Folic acid (1 mg/1) + Niacin (3 mg/1) Capsule Oral U.S. Pharmaceutical Corporation 2009-04-27 Not applicable US
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- H7426RGB3L
- CAS number
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Recruiting Treatment Iron Deficiency Anemia of Pregnancy / Iron Storage Disease 1 4 Terminated Treatment Anemia 1 1, 2 Unknown Status Treatment Postpartum Anemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule, gelatin coated Oral Tablet Oral Capsule, liquid filled Oral Tablet, film coated Oral Tablet, coated Oral Kit Oral Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 03, 2015 16:51 / Updated at September 28, 2021 21:54